Abstract
Anti-coagulation is almost always recommended during management of acute coronary syndromes (ACS). The use of anti-coagulants has been found to reduce mortality, recurrent ischaemic events and stent thrombosis in both medically as well as invasively managed patients. This chapter summarises pathophysiology of thrombosis and the current available evidence for anti-coagulation in ACS. The characteristics of various anti-coagulants along with their dosage and duration of therapy have been discussed. The present recommendations of the American Heart Association and the European Society of Cardiology regarding the use of anti-coagulants in ACS have been compared. The evolving role of newer oral anti-coagulants in ACS has also been briefly discussed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
